R&D News | pharmaphorum

Wednesday 1 April 2026

News

News

Boy in a wheelchair looking out to the forest

Regenxbio, Solid report data with Duchenne gene therapies

Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta's Elevidys.

News

Immutep investors spooked by LAG-3 failure in lung cancer

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

News

Evotec site at Abingdon

Evotec slashes staff as turnaround plan gathers pace

Evotec has announced the next phase of its company overhaul, dubbed Horizon, that will see 800 people lose their jobs in a bid to cut €75m in costs.

News

Vertex chief executive Reshma Kewalramani

Vertex preps FDA filing for IgAN drug after phase 3 readout

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

Uğur Şahin and Özlem Türeci

BioNTech bigwigs will step down to form new mRNA company

The co-founders of mRNA specialist BioNTech – husband and wife team Uğur Şahin and Özlem Türeci – have said they are leaving to set up a new company.

News

BMS hq

BMS eyes another celmod filing in myeloma after phase 3 win

Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.